Trinity Biotech is partnering with Latch Medical to combine its AI-native CGM+ wearable biosensor platform with Latch’s Pharma Latch intradermal drug-delivery technology to create a integrated metabolic health platform focused on diabetes, obesity, and related conditions. The collaboration aims to use real-time CGM+ metabolic data to guide precision drug delivery, advancing from monitoring to therapeutic decision-making with potential regulatory submissions for the Pharma Latch devices. Trinity has also signaled an equity investment in Latch Medical as part of the partnership, signaling strategic alignment and long-term collaboration. The initiative emphasizes the convergence of advanced biosensing, artificial intelligence, and precision intradermal delivery to enable personalized and responsive therapies. Analysts describe the move as a strategic step to deepen Trinity’s role in next-generation metabolic care, while industry coverage notes the financial and investment context around the deal. The announcements highlight a broader push to integrate sensing, AI insights, and targeted delivery to improve patient outcomes in metabolic health.